Analyst consensus rating
Rapport Therapeutics Analyst Rating: Strong Buy
Direct answer
Rapport Therapeutics's consensus rating is Strong Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $64.21.
Forecast evidence checked November 12, 2026.
Get free Rapport Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $27.02
- Average price target
- $64.21
- High price target
- $89.00
- Low price target
- $47.00
- Low target gap
- +73.9%
- Target upside
- +137.7%
- High target gap
- +229.4%
- Target range width
- 155.4%
- Consensus rating
- Strong Buy
- Analysts
- 14
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rapport Therapeutics?
Rapport Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $64.21.
How far are Rapport Therapeutics's low and high targets from the recorded price?
The low target implies +73.9%, while the high target implies +229.4%.
How many analysts are included in Rapport Therapeutics's consensus?
The verified consensus includes 14 analysts.
How is Rapport Therapeutics's target upside or downside calculated?
The average target of $64.21 is divided by the recorded price of $27.02, then one is subtracted to produce +137.7%. This does not guarantee a future return.
When was Rapport Therapeutics's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.